Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
申请人:BioCryst Pharmaceuticals, Inc.
公开号:US06562861B1
公开(公告)日:2003-05-13
Compounds I-III wherein U is CH, O, or S; Z is mono- or di-substituted carbon; R is (CH2)nCO2H, (CH2)nSO3H, (CH2)nPO3H2, (CH2)nNO2, CH(SCH3)3, esters; R1 is H, hydroxyalkyl, aminoalkyl, alkoxyalkyl; RR1 is O; n is 0-4; R2, R3 is H, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkyl; R4 is (CH2)nOH, (CH2)nNH2, substituted alkyl were prepd. as neuraminidase inhibitors. Thus, (1R,3R,4R,1′S)-(−)-(1′-acetylamino-2 ′-ethyl)butyl-4-(aminoimino)methylaminocyclopentan-1-carboxylic acid was prepd. and tested in vitro as neuraminidase inhibitor (IC50<1.mu.M).
化合物I至III,其中U为CH、O或S;Z为单取代或双取代碳;R为(CH2)nCO2H,(CH2)nSO3H,(CH2)nPO3H2,(CH2)nNO2,CH(SCH3)3,酯类;R1为H,羟基烷基,氨基烷基,烷氧基烷基;RR1为O;n为0-4;R2,R3为H,羟基烷基,氨基烷基,烷氧基烷基,卤代烷基;R4为(CH2)nOH,(CH2)nNH2,取代烷基,作为神经氨酸酶抑制剂进行制备。因此,制备了(1R,3R,4R,1′S)-(-)-(1′-乙酰氨基-2′-乙基)丁基-4-(氨基亚氨基)甲基氨基环戊烷-1-羧酸,并在体外作为神经氨酸酶抑制剂进行了测试(IC50<1.mu.M)。